A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This Phase II pilot study is a randomized, double-blind, placebo-controlled study to evaluate
the safety, tolerability, PK, PD, and exploratory clinical efficacy of vamorolone 500mg
(250mg for body weight <50 kg) daily administered orally compared to placebo over a treatment
period of 24 weeks in males with BMD.